Watson Next Target As Purdue Protects Insomnia Drug Patent

Law360, New York (August 30, 2012, 1:28 PM EDT) -- Purdue Pharmaceutical Products LP on Monday expanded its efforts to protect its insomnia treatment Intermezzo, leveling a new patent infringement suit against Watson Pharmaceuticals Inc. in New Jersey federal court.

In allegations closely resembling those lodged against generic-drug maker Actavis Inc. last week, Purdue says Watson is seeking regulatory permission to manufacture its own Intermezzo clone, in violation of Purdue’s patent rights. The patent-in-suit is U.S. Patent Number 7,682,628, titled “compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof,” issued to...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.